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Anti-enolase antibodies partially protective against 
systemic candidiasis in mice 
HannekeJ. van Deventer, Wil H. Goessens, ArjenJ van Vliet and Henvy A. Verbrugh 
Department of Clinical Microbiology and Antimicrobial Therapy, Erasmus University Rotterdam, 
The Netherlands 
Objective: The evaluation of the effect of protective capacities of antibodies directed against the immunodominant 
enolase antigen of C. albicans on the survival rate of mice with systemic candidiasis. 
Methods: Passive transfer of heterologous rabbit antibodies (IRS) directed against a crude Candida albicans extract 
and homologous mice anti-enolase antibodies (IMS) in a non-acute but lethal systemic Candida model in mice. 
Results: Protection could only be demonstrated by repeated administration of homologous as well as heterologous 
immune sera. The protective effect was not due to  non-specific, heat-labile, serum factors, since fractionated anti- 
cytoplasmic rabbit immunoglobulins also gave a decreased mortality rate. These findings could not be ascribed to 
enhanced opsonization as observed in in vitro opsonization experiments using peritoneal macrophage monolayers. 
Conclusions: Anti-enolase antibodies are partially protective against lethal C. albicans infections. The protection was 
not due to enhanced initial clearance of viable C. albicansfrom the internal organs, but was presumably the result of as 
yet unknown effects of antibodies occurring later in the infectious process. 
Key words: Anti-enolase antibodies, systemic candidiasis, immunoprotection 
INTRODUCTION 
Candidiasis represents a spectrum of diseases ranging 
from colonization of the skin or niucous membranes to 
severe and often fatal disseminated disease. Conse- 
quently, it is to be expected that a variety of host 
immune mechanisnis interact in the response to 
Candida albicans. There is now a body of evidence 
showing that cellular elements, including the neutro- 
phil, the helper T-lyniphocyte and the nionocyte/ 
macrophage, play an important role in the defense 
against fungal infections 11-51, I n  contrast, evidence 
pertaining to antibody-mediated defense against candi- 
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diasis is contradictory and, consequently, its role in the 
pathogenesis of Candida infections is poorly under- 
stood. Maiti et al. [6] gathered indirect evidence 
supporting a role for specific antibodies in protection 
against Candida infections in mice. Several authors have 
failed to demonstrate the protective role of antibodies 
in passive ininiunization experiments [7,8], whereas 
others succeeded in demonstrating direct protective 
effects by transfer of hyperimmune serum in Candida 
infections in mice [9-1 I ] .  Some authors have found a 
protective effect only after vaccination with viable C. 
albicuizs cells [12,13]. 
No overall conclusion can, thus, be drawn at this 
time about specific antibody protection against candi- 
diasis, since different treatment schedules of iinniune 
sera directed toward various antigenic determinants 
have been used. Also, experiments were perfornied in 
different animal models of invasive infection. 
In the present study, we evaluated the protective 
capacities of antibodies directed against the ininiuno- 
dominant enolase antigen of C.  albicans, and compared 
its activity to that of antibodies directed against a crude 
C. ulbirans antigen extract. A non-acute but lethal 
systemic candidiasis mouse niodel was chosen because 
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it was deemed to be inore relevant clinically than 
previously published more acute, lethal infection 
models. Furthermore, in vitro phagocytosis and killing 
of C. albicans by macrophage monolayers were studied. 
MATERIALS AND METHODS 
Candida strains 
Throughout all in vivo and in vitro experiments, C. 
albicarzs strain ATCC 44858 was used. For preparation 
of the crude antigen extract and of purified enolase 
antigen, C. ulbicuizs CBS 5982 serotype A (Centraal 
Bureau voor Schimmelcultures, Delft, The Nether- 
lands) was used. 
Preparation of anti-cytoplasmic immunoglobulins 
Antisera were obtained by immunizing New Zealand 
White rabbits with a crude C. albicans antigen extract, 
prepared as described elsewhere [14]. Briefly, the crude 
antigen was prepared from C. albicans (CBS 5982 
serotype A, Centraal Bureau voor Schinimelcultures) 
by disruption with glass beads. Cell walls were spun 
down a t  5000 2 a t  4 °C  for 45 inin and the supernatant 
was again centrifuged at 40,000 g at 4°C for 30 min 
(Beckman JA20). The final supernatant was lyophilized 
and stored at  -20°C. 
The animals were repeatedly injected subcutan- 
eously with 12 mg of crude antigen in Ribi adjuvant 
(Ribi Immunochem, Research, Inc., Montana, USA). 
The antibodies directed against the crude antigen 
determinants were monitored by ELISA using the 
crude antigen. This polyclonal polyspecific antiserum 
was pooled and kept frozen at -80°C. Antibodies 
directed towards mannan were evaluated by counter- 
immunoelectrophoresis (CIE) and crossimmuno- 
electrophoresis (XIE), techniques which have 
previously been described [l 51. Mannan was removed 
from the crude antigen by the use of affinity 
chromatography on concanavalin A Sepharose 4B 
(Pharmacia LKB, Uppsala, Sweden) according to the 
method of Ellsworth et al. [16]. 
Immunoglobulin fractionation 
Fractionation of immunoglobulins from rabbit sera was 
performed by ammonium sulfate precipitation at 4 "C. 
Ten milliliters of serum, diluted with an equal volume 
of 10 mM Tris in 0.9% NaCl (pH 7.6), was brought to 
50% saturation by adding a saturated solution of 
(NH&S04. After 30 min at room temperature the 
suspension was centrifuged at 1700 g for 15 min. The 
pellet was dissolved in 0.9% NaCl and brought to 40% 
saturation by adding a saturated solution of (NH4)2S04. 
Again the solution was left at room temperature for 30 
min and centrifuged at 1700 g for 15 min. This 
procedure was repeated for 33% saturation. The pellet 
was dissolved in 5 mL sterile phosphate-buffered saline 
(PBS) and dialyzed against sterile PBS overnight. The 
titer of anti-Candida antibodies in this immunoglobulin 
fraction was equal to the titer of anti-Candida anti- 
bodies of the initial serum, as determined by ELISA. 
The immunoglobulin fraction of immune rabbit serum 
(IRS) will be designated as IgIRS, and the immuno- 
globulin fraction of normal rabbit serum (NRS) as 
IgNRS. 
Preparation of anti-enolase immunoglobulins 
Antisera to enolase were raised in BALB/c mice (Iffa 
Credo, L'Arbresle, France) by repeated immunization 
with purified enolase. Purification of C. albicans 
enolase has been described previously [16]. Mice were 
repeatedly injected subcutaneously with SO pg of 
purified enolase in Ribi adjuvant (Ribi Immunochem). 
Anti-enolase antibody levels were monitored by ELISA 
[ 171, using enolase as the antigen. This polyclonal 
monospecific anti-enolase antiserum from several mice 
was pooled and stored at -80 "C. Specificity of the anti- 
enolase antibodies was determined by Western blotting 
using the crude antigen extract of C. albicans. Pro- 
cedures for gel electrophoresis and immunoblotting 
were similar to those used in previous studies [I 81. 
Preparation of a monoclonal antibody (MAb) against 
mannan 
Immunization of 14-week-old BALB/c mice (Iffa 
Credo) was performed with 500 pg of crude antigen 
emulsified in an equal amount of complete Freund's 
adjuvant (0.1 mL) (Life Technologies B.V., Breda, The 
Netherlands) as described by Mirza et al. [19]. For MAb 
production the draining lymph nodes were removed 
and pooled for fusion with the mouse myeloma cell line 
SP 2/0, as described by Ollert and Calderone [20]. 
From one clone, ascites was produced and characterized 
by immunoblotting, CIE and XIE. Ascites was dialyzed 
against sterile PBS and diluted four times in sterile PBS 
before use. The MAb is an IgG class of antibody, and 
will be denoted as 18C11. 
ELISA to determine anti-crude antigen antibodies 
Highly activated polystyrene microtiter plates (Nunc 
Immunoplate Maxisorp F96) were coated with 0.3 pg 
of crude antigen in 100 pL of coating buffer (0.13 M 
sodium carbonate and 0.03 M hydrogenated sodium 
carbonate [pH 9.61) per well and were subsequently 
incubated overnight at 4°C. The plates were washed 
twice with 200 pL ofTBS block (0.01 M Tris, 0.15 M 
NaCl [pH 7.61, 0.1% gelatin) per well and were then 
incubated with 200 pL of TBS block per well at  37°C 
for 2 h. The plates were then drained. Immune sera or 
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the immunoglobulin fractions were diluted twofold in 
TBS (0.01 M Tris, 0.15 M NaCl [PH 7.61) starting at 
a dilution of 1:50. A total of 50 pL of each serum or 
immunoglobulin fraction was added to each well, and 
plates were subsequently incubated at 37 "C for 60 nun. 
After three cycles of washing with TBSt (TBS with 
0.04% [wt/v01] gelatin and 0.05% [vol/vol] Tween-20), 
50 pL of an alkaline phosphatase-labeled goat anti- 
rabbit IgG conjugate or, for detection of mouse 
antibodies, 50 pL of a rabbit anti-mouse IgG conjugate 
(both diluted 1:lOOO in TBSt before use [Sigma 
Chemical Co., St Louis, Mo]) was added to each well; 
this was followed by incubation for 1 h at 37 "C. A 100- 
pL volume of acid enzyme substrate solution (9.7% 
diethanolamine, 3 mM NaN3, 5 mM MgC12.6H20, 1 
mg/mL p-nitrophenylphosphate [Sigma]) was added 
after three cycles of washing with TBSt, and the plates 
were incubated at 37°C in the dark. Color 
development was stopped after 30 min of incubation by 
adding 100 pL of 3 M NaOH to each well. The optical 
densities at 405 nm were determined by using an 
automated plate reader (Bio-Tek Instruments, Inc., 
Winooski, Vt). 
Protective role of various immune sera and 
immunoglobulin fractions in mice 
Twelve- to 13-week-old specific-pathogen-free 
BALB/c mice (Iffa Credo, l'Arbresle, France) were used 
for in vivo experiments. Four hours before mice were 
infected by intravenous inoculation of 3 x lo5  colony- 
forming units (CFU) of C. albicuns into the tail vein 
[21], mice were intraperitoneally inoculated with 0.4 
mL of IRS or immune mouse serum (IMS) or with 
IgIRS. Additional doses of 0.3 mL of sera were given 
at 6, 12 and 18 days after infection. NRS or normal 
mouse serum (NMS) or MAb 1 8 C l l  or PBS served as 
negative controls, as indicated. 
At SO days after infection, surviving mice were 
killed, and their kidneys, lungs, liver and spleen 
quantitatively cultured for C. albicuns 1211 on Sabouraud 
dextrose agar (Oxoi'd, Basingstoke, England). 
Macrophage monolayers 
For macrophage monolayers a modified method of van 
Etten et al. 1221 was used. Briefly, macrophages were 
obtained from peritoneal cavities of 12-13-week-old 
specific-pathogen-free BALB/c mice (Iffa Credo). The 
macrophages were washed twice in Dulbecco's 
modified Eagle's medium (Flow Laboratories, Irvine, 
Scotland) supplemented with 1% glutamine. Mono- 
layers of peritoneal macrophages were cultured at  37 "C 
on chamber slides (Lab-Tek, Bayer, The Netherlands) 
under a fully humidified atmosphere of 7.5% CO2 in 
air in culture medium containing Dulbecco's modified 
Eagle's medium with 5% inactivated fetal bovine serum 
(FBS; Hy-Clone, Logan, Utah). After the first 2 h of 
incubation, fresh culture medium was added to the 
monolayer, and the macrophages were incubated for 
24 h. After this incubation period, preopsonized C. 
ulbicans cells were added to the monolayers, resulting in 
a C. utbicundmacrophage ratio of 1O:l. C. ulbicans was 
preopsonized by incubation of a washed stationary- 
growth-phase suspension with 10% of indicated sera or 
immunoglobulin fractions under continuous rotation at 
8 rev/min for 15 min at 37"C, and subsequent washing 
of the yeast cells in PBS twice. 
After a 5- or 10-min uptake period, the non- 
ingested yeasts were removed by washing the 
monolayer three times with cold PBS. The monolayer 
was fixed in methanol and stained with May- 
Grunwald-Giemsa, after removal of the plastic 
chamber from the slide. The uptake of C. nlhicuns was 
determined microscopically, and expressed as percen- 
tage of phagocytosing macrophages and as the average 
number of Cundida cells per macrophage. Intracellular 
killing was performed as described by van Etten et al. 
1221 and determined after a 5- and 10-min uptake 
period. 
Statistical analysis 
Statistical evaluation of the differences in the survival 
curves between serum-treated, immunoglobulin- 
treated and PBS-treated groups was performed by using 
the log rank test. This test examines the decrease in 
survival with time as well as the eventual percentage of 
survival. The Kruskal-Wallis test was used for evalua- 
tion of the differences in the percentage of phagocytosis 
in the in vitro assays between the various opsonized C. 
ulbicans cells. 
RESULTS 
Characterization of raised immune sera 
Characterization of the immune sera was performed by 
Western blotting, CIE and XIE techniques. The IMS 
reacted as a single band in the immunoblot, and IRS 
reacted with multiple antigenic determinants of 20 
to 90 kDa, including the enolase antigen (45 kDa) 
(Figure 1). IRS did not react with mannan as was found 
by CIE and XIE using purified mannan as antigen (data 
not shown). 
The MAb 18C11 did not recognize any protein by 
immunoblotting; it only reacted with mannan, as 
demonstrated by XIE (data not shown). Titration ofthe 
MAb 1 8 C l l  by CIE resulted in an anti-mannan titer 
of 1:256. NKS or NMS did not react with Cundida 
antigens as determined by immunoblotting (Figure l),  
ELISA or CIE (data not shown). 
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Figure 1 Western blotting analysis of IMS and IRS using 
the crude C. albicans antigen as antigen extract. Lane 1: 
Coomassie-stained crude antigen. Lanes 2 and 3: IMS. 
Lane 4: IRS. Lane 5: NMS. Molecular mass markers are 
indicated on the left (kUa). 
Protective role of IRS 
Serial blood samples were collected from mice given 
IRS, in  order to study the length of time for which the 
anti-C. albicans antibodies remained detectable in the 
blood after imniunotransfer. Antibody titers against 
the crude C. albicans antigen and purified enolase were 
determined (Table 1). It was found that after 
administration of 0.4 mL of IRS to uninfected mice, 
antibodies directed towards the crude antigen decreased 
over 1 4  days but did not completely disappear. I n  sera 
of mice with systemic candidiasis, however, anti- 
enolase antibodies and anti-crude antigen antibodies 
decreased much more rapidly. Fourteen days after 
administration, titers decreased to  under the detection 
limits of the respective assays. In order to maintain a 
constant level of antibodies it was, therefore, decided to 
give IKS repeatedly at intervals of 6 days. 
In subsequent challenge experiments mice treated, 
for a total of four injections, with the IRS (n=21) 
showed a significant delay in mortality (Figure 2; 
p=0.003). In contrast, mice treated with NRS ( ~ ~ 2 2 )  
or  PBS (rt=27) all died within 3 weeks, most within 2 
weeks (Figure 2). No significant differences were found 
in  survival between the PBS-treated and NKS-treated 
mice (p=0.25). The three IKS-treated mice still alive 
at day SO were killed to  obtain quantitative cultures of 
Table 1 Antibody titers, expressed i n  OUj(,s values, against 
the crude antigen and enolase in sera of mice after a single 
transfer of IRS, monitored over 14 days in infected and 
uninfected mice 
Crude C albiranns antigen,' Enolae antigcn" 
Time after Uninfected lnftrted Infectcd 
Inimunotransfcr niire llllce IIllCe 
1 11 
1 day 
7 days 
14 days 
3 days 
0.605h 0.700 0..540 
0.545 0.654 0.142 
0.583 0.513 0.OiX 
0. .544 0.172 0.028 
0.482 0.0 0.0 
'Antigen used in ELISA in determining anti-C. albiruns antibodies. 
"Optical densities at  405 nm at a serum dilution of 1 : ~ ) .  
the organs. Lungs, liver and spleen were sterile, whereas 
cultures of the kidneys revealed 1.7, 5.1 and 3.1 log 
CFU of C. albicans. Sera determined for two of the 
surviving mice had high titers of autologous antibodies 
against the enolase and lower antibody titers against the 
crude antigen (Table 2). Note  that the sera of mice 
surviving at day 50 did not contain hetero-logous rabbit 
anti-Candida antibodies any more. 
Protective role of IglRS fraction 
To rule out  the possibility that the observed protective 
effect of IRS was due to  non-specific serum factors, the 
20 :i_L 0 0 * . .  . .  .I- ...... ; _____, * I  I I 1 . I /  I I 
6 12 18 24 30 36 
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C.albicans 
Figure 2 Effect of repeated administration of IRS or 
IgIRS on survival of imniunocompztent mice with 
candidiasis. Mice were treated intraperitoneally with 
0.4 niL IRS (0) or  IgIRS (0) 4 h before intravenous 
inoculation with 3 x 10' CFU C. alhirans and treated with 
0.3 mL IRS or IgIRS at 6, 12 and 18 days after Candida 
inoculation. Control mice were likewise treated with NRS 
(v) or PBS (+). Number of mice treated was: IKS, n=21; 
IgIKS, tz=17; NRS, n=22; PBS, n-27. * p =  0.003 and 
*p <0.001 versus NRS- or PBS-tredted mice recpcctively, 
**p=0.003 versus PBS-treated mice. 
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IRS was fractionated to obtain purified rabbit 
immunoglobulins. Again the mice treated with IgIRS 
(n=17), given for a total of four injections, showed a 
significant delay in mortality compared to the PBS 
group (n=27) (Figure 2; p=0.003). The IgIRS 
provided protection equal to that of complete IRS 
(p=0.77). The three IgIRS-treated mice still alive at 
day 50 were killed. For one mouse, all internal organs 
were sterile. From the other two mice, Candida was 
cultured from the kidneys (respectively 3.5 and 4.8 log 
CFU of Candida/two kidneys). Again, sera deter- 
mined for two of the surviving mice revealed high titers 
of autologous anti-enolase antibodies and less anti- 
crude antigen antibodies (Table 2). 
Vfi * 
I ,  
0 
I Y I  . , I I ! 
Protective role of IMS 
From the above described experiments it was not clear 
which antibody or antibodies were responsible for the 
protective effect observed. The IMS administered to 15 
mice repeatedly for a total of four injections, targeted 
specifically toward the enolase antigen, induced a 
significant delay in mortality in comparison to NMS 
( ~ ~ 1 0 )  or PBS (n=27) (Figure 3; p=0.005 and 
p=0.015, respectively). NMS did not provide 
protection; the mortality rate was similar to that of the 
PBS-treated controls. Two of the 15 IMS-treated mice 
still alive at day 50 were killed. C. albicans was only 
cultured from the kidneys (respectively 1.7 and 5.2 log 
CFU of C. albicandtwo kidneys); the other internal 
organs were sterile. Both mice had higher titers of anti- 
enolase antibodies than antibodies to the crude antigen 
extract (Table 2). 
The specificity of the protective effect of the anti- 
enolase IMS was also confirmed by treating mice with 
an anti-mannan monoclonal antibody (n=19) which 
did not show any protective effect (Figure 3). 
To gain more insight into the potential mechanisms 
of the protective effect of the IMS, mice were sacrificed 
1, 2 and 3 days after the onset of infection. Control 
Table 2 Antibody against enolase and the crude antigen 
extract in IRS-, IgIRS- and IMS-treated mice surviving 
C. ulbicunr intravenous challenge for 50 days 
Mouse transfer Anti-enolase Anti-crude antigen 
with: antibodies" antibodiesa 
IRS 
IKS 
IgIRS 
IgIRS 
IMS 
IMS 
0.479b 0.118 
0.764 0.098 
2.107 0.046 
1.079 0.070 
1.217 0.281 
0.266 0.070 
"Determined by using anti-mouse IgG conjugate. 
boptical densities at 405 nm at a serum dilution of 1:400. 
looTiii 
4 time (days) 
3 1 0 5 m  
C.albicans 
Figure 3 Effect of repeated administration of IMS or MAb 
18C11 on survival of inimunocompetent mice with 
canhdiasis. Mice were treated intraperitoneally with 0.4 mL 
IMS (0) or MAb 18Cll (v) 4 h before intravenous 
inoculation with 3 x lo5 CFU C. albicuns and treated with 
0.3 mL IMS or MAb 18Cll at 6 ,  12 and 18 days after 
Cundidn inoculation. Control mice were likewise treated 
with NMS (0) and PBS (+). Number of mice treated was: 
IMS, n=15; MAB 18Cl1, n=19; NMS, n=10; PBS, 
n=27. *psO.O05 versus NMS-treated mice, *p=O.O15 
versus PBS-treated mice. 
mice treated with NMS and PBS were sacrificed at the 
same intervals. Quantitative cultures from their internal 
organs showed that administration of the IMS had no 
modulating effect on the number of C. albicans cells per 
organ during the initial 3 days after initiation of 
infection, as compared to the mice treated with NMS 
or PBS (Table 3). Similar results were found when the 
inoculum size was reduced to 4 x lo4 CFU (data not 
shown). 
In vitro phagocytosis experiments 
To study the influence of antisera against enolase on the 
phagocytosis and killing of C. albicans by macrophages, 
in vitro opsonization experiments were performed 
using peritoneal macrophage monolayers as indicator 
cells. Phagocytosis was determined after a 5- and 10- 
min incubation period, since after 30 min Candida 
already started to form germ tubes, which influenced 
the reproducibility of the assay. From the data in Table 
4 it can be seen that after 5 min of incubation, 
differences in percentages of C. albicanr phagocytosis 
were not significant between cells preopsonized with 
IRS, N R S  and their respective immunoglobulin 
fractions or their heat-inactivated form. However, at 
10 min of incubation macrophages had taken up 
significantly higher numbers of IRS- and NRS- 
preopsonized C. albicans cells compared to cells 
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Table 3 CFU of C. albicans per indicated organ at days 1, 2 and 3 after inoculation with 3 x 1 O5 CFU C. albicans of mice 
given IMS, NMS or PBS 4 h before 
Day 1 after inoculation Day 2 after inoculation D:iy 3 after inoculation 
Organ IMS NMS PBS IMS NMS PBS IMS NMS 1'BS 
Spleen 4.02 3.9 4.3 3.6 3.8 4.0 4.16 3.8 3.8 
Kidneys 5.0 4.9 5.1 5.4 5.9 6.5 6.9 6.4 6.6 
Lung 3.0 2.8 3.0 2.9 2.7 3.3 3.6 2.9 3.1 
Liver 4.6 4.5 4.7 4.2 4.3 4.5 4.7 4.4 4.3 
'Log CFU of C. albicaws (niean of two mice). 
preopsonized with IgIRS, IgNRS, heat-inactivated 
IKS or NRS. Also, the percentage of macrophages 
participating in the phagocytic process was significantly 
higher (p < 0.05; Kruskal-Wallis test) in these cases. 
Phagocytosis of IRS-opsonized Candida at 10 nlin of 
incubation did not significantly differ from that of the 
NRS-opsonized yeast cells (Table 4). 
Similar results were observed for fresh IMS com- 
pared to heat-inactivated IMS and fresh NMS 
compared to inactivated NMS (Table 5). Already after 
5 inin of incubation phagocytosis of C. albicans 
opsonized with fresh anti-enolase serum was signi- 
ficantly higher than that of yeast opsonized with heat- 
inactivated anti-enolase serum. Phagocytosis of 
IMS-opsonized Candida at 5 inin of incubation did not 
significantly differ from that of NMS-opsonized yeast 
cells (Table 5). A lower percentage of phagocytosing 
macrophages as well as a smaller number of C. albicans 
cells per macrophage were observed if heat-inactivated 
IMS was used to opsonize the Candida cells. Although 
the MAb 18Cll binds well to the cell wall of C .  
albicans, as determined by immunofluorescence, it did 
not promote phagocytosis. In fact, phagocytosis rates of 
18C1l-opsonized cells were similar to those of the PBS 
controls (Table 5). 
Table 4 Effect of crude antigen antisera and purified 
antibody on phagocytosis of C. albicans 
C. albicans cells % phagocytosing 
per inacrophage macrophages 
Opsonin 5 min 10 niin 5 min 10 min 
IRS 2.420.54 4.23f0.6" 5926 8 6 f 4 "  
NKS 2.7k0.8 4.17f0.9h 56+6 83k3' 
IRS1nzCtlVatCd 1.64i0.11 2.25t0.04 3 4 f 1 2  6 6 2 2  
NRSIIIX'UVXC~ 2.09f0.11 2.27f0.04 5 2 f 5  5 9 i 1  
IgIRS 2.19f0.44 3.19f0.5 4 8 f 7  6 6 f 6  
IgNRS 1.58i0.48 2.55f0.23 5 2 f 5  7 0 f 6  
'IRS significantly different from IRS'n""'"ted and IglRS ( p <  0.05; 
Kruskal-Wallis test). 
bNRS significantly different from NRS'n""'""d and IgNRS 
(p<0.05; Kruskal-Wallis test). 
We were not able to detect killing of C. albicans by 
the peritoneal macrophages regardless of the opsonins 
used to pretreat the yeast cells. 
DISCUSSION 
Several studies have described delayed mortality after 
the administration of specific antibodies in animal 
models of deep-seated candidiasis [6,9-111. Antibodies 
used were mostly polyclonal and raised against a variety 
of undefined Candida antigens. Matthews et al. [ l l ] ,  
however, demonstrated protection which was achieved 
by the administration of antibodies specifically directed 
toward a 47-kDa immunodominant antigen. 
in the present study we evaluated the effect on 
mortality in a model of chronic, but ultimately fatal, 
candidiasis of antibodies raised against a variety of 
undefined antigens (IRS) and against the specific 
enolase antigen (IMS). The reason for studying anti- 
enolase antibodies for their protective capacities is 
that enolase has been shown to be an immunodominant 
antigen in patients with invasive candidiasis [17]. In this 
Table 5 Effect of anti-enolase antibodies on phagocytosis 
of C. albicans 
C. albicans cells % phagocytosing 
per macrophage macrophages 
Opsonin 5 min 10 inin 5 min 10 niin 
IMS 2.65i0.7" 3.33f0.78^ 5 9 f 6 "  70k6' 
NMS 2.3k0.11b 2.84f0.51' 53f7"  44+12 
IMymmvared 1.67k0.02 1.88k0.17 22+3 4 7 f 7  
N M S I n X C t I m C C d  1.2920.12 1.73i0.03 5 k 1  3 0 f 6  
18C11 1.83k0.46 2.69k0.78 1 6 f 3  39?10 
PBS 2.14k0.26 2.39fO.17 10k5 32+7 
alMS significantly different from IMS'"a"'"~'t'd, 
18Cl l  and PBS (p<0.05; Kruskal-Wallis test). 
Kruskal-Wallis test). 
'IMS significantly different from all other opsonins (j60.01; 
Kruskal-Wallis test). 
IMSzanti-enolase antigen mouse serum: NMS=normal mouse 
serum; 18C1 l=monoclonal anti-mannan antibody. 
NMS"laCf""'"', 
hNKS significantly different from NMS"'"'f'""'ed (p'0.05; 
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respect enolase is comparable to the immunodominant 
47-kDa breakdown product of the 90-kDa heat shock 
protein [12]. As Mourad and Friedman [9] reported 
that the mortality rate became similar to that of controls 
if the administration of antibodies was prematurely 
stopped, the design of a study aimed at demonstrating 
protection should assure a sufficient and constant 
antibody level in the blood of the experimental animal. 
Fulfilment of these conditions was achieved in our 
study by repeated injections of the antisera at  intervals 
of 6 days. Experiments in which antiserum was 
administered only once, 4 h before initiation of in- 
fection, failed to show any protective effect (data not 
presented). These findings might also explain the results 
of Kagaya et al. [23], who reported lack of effectiveness 
of specific immunoglobulins administered only once 
every 2 weeks. 
A protective effect in our model could only be 
shown in mice which had received three repeated doses 
of IRS, IgIRS or IMS. All three regimens had similar 
protective effects. The experiment in which mice were 
treated with IgIRS indicates that the protective effect 
is largely mediated by the antibodies present in the 
immune sera and is not due to non-specific heat-labile 
serum factors. The IMS we used is a well-defined 
polyclonal antiserum, specific for enolase. In contrast, 
IRS was directed towards various undefined antigenic 
determinants of several molecular weights, as well as 
against enolase, present in the crude Candida extract. 
The results obtained with the IMS correlate well with 
the findings of Matthews et al. [l 11, who also demon- 
strated a protective effect with an antiserum directed 
specifically against another (47-kDa) immunodoniiiiant 
antigen. The specificity of the protective effect of anti- 
enolase antibodies was underlined by the results of the 
MAb 18Cl l .  
Another finding which underlines the potential 
protective effect of anti-enolase antibodies is the fact 
that mice surviving for 50 days after the (3andida 
challenge have high levels of circulating anti-enolase 
antibodies; this would indicate that these mice have, by 
that time, developed antibodies against the enolase that 
may have helped to extend their survival. These anti- 
bodies had to be of mouse origin, as indirectly proven 
in animals given IRS or IgIRS who had high pro- 
portions of autologous mouse anti-enolase antibodies. 
To gain insight into the mechanism(s) of decreased 
mortality observed with immune sera, the lungs, liver, 
spleen and kidneys of mice sacrificed during the first 3 
days were cultured. No significant effect on the number 
of C. alhicans cultured in these organs was observed after 
IMS treatment. From this it is concluded that the 
protective effect is not the result of an early decrease in 
the number of viable CFUs per organ. Presumably, 
effects of immune sera occur later in the infection 
process, as suggested by others 124,251. 
The effect of immune sera (IMS and IRS) could 
not simply be explained by enhancement of the 
phagocytic process by leukocytes or macrophages 
through an opsonic mechanism. In in vitro experi- 
ments increased uptake was seen with the IMS- or 
IRS-opsonized C. alhicans cells; however, in the control 
experiments using non-immune sera, similar increases 
in Candida uptake were observed. From these opsono- 
phagocytosis experiments it became clear that the 
opsonic effect of immune serum is to a significant 
degree dependent upon complement activation, since 
heat-treated sera were much less opsonic. Although 
complement promoted the rate of phagocytosis, it did 
not enhance the intracellular killing of C. albicans by 
peritoneal niacrophages, as was postulated by Pereira 
and Hosking [26]. Surprisingly, monoclonal anti- 
mannan antibodies did not enhance phagocytosis, 
although the antibody clearly bound to the surface of 
the Candida cells. Lack of opsonic activity of this IgG 
class antibody is not expected and in any case points to 
an inability to interact with FC receptors on the 
macrophage. 
Another somewhat puzzling finding is the fact that 
most of the internal organs of the mice surviving at day 
50 were sterile, except for the kidneys. This failure to 
clear Candida from the kidneys might imply that the 
anti-Candida activity of antibodies is anatomically 
restricted. Sohnle et al. 1271 reported that the infil- 
tration of monocytes into infectious loci is enhanced in 
the presence of antibodies. However, histopathologic 
examinations, even in imniunized mice, showed 
infiltration of granulocytes predominantly and less so of 
mononuclear cells in the kidney, which slowly changes 
at  varying times after challenge with C. albicans 1251. 
This slow infiltration of mononuclear cells may help 
explain the unique susceptibility of the kidney to 
Candida infections [25], which would restrict antibody- 
mediated protection through mononuclear cells to only 
the later stages of Candida infection. Inimunotherapy 
with specific antibody, therefore, seems to protect 
predominantly the organs of the reticuloendothelial 
system, whereas other interactions are needed to 
enhance resistance against renal candidiasis 1251. 
There are still a number of remaining questions 
concerning to the mechanism involved in these 
antibody protective effects. It  is likely that antibody- 
dependent antigen presentation to T-cells is involved, 
allowing earlier recognition of C. alhicans cells, probably 
combined with enhancement of cell-mediated mech- 
anisms, which might have resulted in increased survival. 
Therefore we conclude, as have others, that protective 
immunity against systemic candidiasis involves a 
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combination of innate defenses, and humoral and 
cellular immunity [28]. 
In conclusion, we have shown that enolase-specific 
antibodies provide partial protection against lethal 
C. ulbicans infections, an observation that warrants their 
further evaluation in future studies. 
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